Gut microbiome (metagenomics) of a patient with Systemic sclerosis disease before low-dose IL-2 treatment
host
Homo sapiens
isolation_source
Six patients from the TRANSREG trial (ClinicalTrials.gov; NCT01988506) had available feces samples collected at baseline and between 3 to 6 months after the first IL-2LD injection.
collection_date
2019-03-01
geo_loc_name
France: Paris
lat_lon
48.8566 N 2.3522 E
replicate
4
treatment
beforeIL2
sequencing
metageomics
background/disease
Scleroderma
BioSampleModel
Metagenome or environmental